ALK-Abelló A/S ALK-Abelló A/S

ALK-Abelló A/S

ALK-B

Pozycja w akcjach #2347
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Cena akcji
$37.79
Kapitalizacja rynkowa
$8.38B
Zmiana (1 dzień)
4.29%
Zmiana (1 rok)
16.81%
Kraj
DK
Handel ALK-Abelló A/S (ALK-B)

Kategoria

Healthcare
EPS dla ALK-Abelló A/S (ALK-B)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy ALK-Abelló A/S, obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla ALK-Abelló A/S od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -
US
$-7.98 -
US
$-5.29 -
AU
- -
CH
$27.74 -
NL